Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages 3346-3353

  Morschhauser, Franck ^a   Leonard, John P ^a   Fayad, Luis ^a   Coiffier, Bertrand ^a   Petillon, Marie Odile ^a   Coleman, Morton ^a   Schuster, Stephen J ^a   Dyer, Martin J S ^a   Horne, Heather ^a   Teoh, Nick ^a   Wegener, William A ^a   Goldenberg, David M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; LACTATE DEHYDROGENASE; RITUXIMAB; VELTUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMMU 106; MONOCLONAL ANTIBODY IMMU-106;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; IMMUNOGENICITY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; B LYMPHOCYTE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; FEVER; HEADACHE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PRURITUS; RECURRENCE; TREATMENT OUTCOME;

EID: 70249106098     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9117     Document Type: Article

References (45)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Traullé C, Coiffier BB: Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol 1:297-306, 2005
3. Marcus R, Hagenbeek A: The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol 67:5-14, 2007 (suppl)
4. Cheung MC, Haynes AE, Meyer RM, et al: Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 33:161-176, 2007
5. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711-4716, 2004
6. Coiffier B, Lepage E, Briére J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
7. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
8. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
9. Hochster HS, Weller E, Ryan T, et al: Results of E1496: A phase III trial of CVP with or without rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 23:556a, 2004 (abstr 6502)
10. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
11. Chambers SA, Isenberg D: Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14:210-214, 2005
12. Silverman GJ: Anti-CD20 therapy and autoimmune disease: Therapeutic opportunities and evolving insights. Front Biosci 12:2194-2206, 2007
13. Cohen SB, Emery P, Greenwald MW, et al: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806, 2006
14. Hauser SL, Waubant E, Arnold DL, et al: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676-688, 2008
15. Dörner T, Burmester GR: New approaches of B-cell-directed therapy: Beyond rituximab. Curr Opin Rheumatol 20:263-268, 2008
16. Martin P, Furman RR, Ruan J, et al: Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol 45:126-132, 2008
17. Genovese MC, Kaine JL, Kohen MD, et al: Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (Ph I/II ACTION study). Arthritis Rheum 54:S66, 2006 (abstr 6)
18. Morschhauser F, Marlton P, Vitolo U, et al: Interim results of a phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma. Blood 110:199a, 2007 (abstr 645)
19. Hagenbeek A, Gadeberg O, Johnson P, et al: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase I/II trial. Blood 111:5486-5495, 2008
20. Coiffier B, Lepretre S, Pedersen LM, et al: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 111:1094-1100, 2008
21. Stein R, Qu Z, Chen S, et al: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10:2868-2878, 2004
22. Goldenberg DM, Rossi EA, Stein R, et al: Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 113:1062-1070, 2009
23. Tahir H, Rohrer J, Bhatia A, et al: Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 44:561-562, 2005
24. Morschhauser F, Leonard JP, Coiffier B, et al: Initial safety and efficacy results of a secondgeneration humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma. Blood 106: 683a, 2005 (abstr 2428)
25. Morschhauser F, Leonard JP, Fayad L, et al: Rituximab-relapsing patients with non-Hodgkin's lymphoma respond even at lower dose of humanized anti-CD20 antibody, IMMU-106 (hA20): Phase I/II results. Blood 108:769a, 2006 (abstr 2719)
26. Morschhauser F, Leonard JP, Fayad L, et al: Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20) in refractory or recurrent NHL: Phase I/II results. Proc Am Soc Clin Oncol 25:449, 2007 (abstr 8032)
27. Harris NL, Ferry JA: Classification of non-Hodgkin's lymphomas, in Knowles DM (ed): Neoplastic Hematopathology (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 691-753
28. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
29. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
30. Cheson BD, Horning S, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999
31. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
32. Genentech: Rituxan (Rituximab) full prescribing information. http://www.gene.com/gene/products/information/oncology/rituxan/insert.jsp
33. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
34. Igarashi T, Kobayashi Y, Ogura M, et al: Factors affecting toxicity, response and progressionfree survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 13:928-943, 2002
35. Foran JM, Rohatiner AZS, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
36. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45: 2047-2055, 2004
37. Berinstein NL, Grillo-Lopez AJ, White CA, et al: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001, 1998
38. Gordan LN, Grow WB, Pusateri A, et al: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096-1102, 2005
39. Cartron G, Blasco H, Paintaud G, et al: Pharmacokinetics of rituximab and its clinical use: Thought for the best use? Crit Rev Oncol Hematol 62:43-52, 2007
40. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
41. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, relapsed low-grade or follicular B-cell lymphoma. J Clin Oncol 15:3266-3274, 1997
42. Glennie MJ, French RR, Cragg MS, et al: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823-3837, 2007
43. Kennedy AD, Beum PV, Solga MD, et al: Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280-3288, 2004
44. Williams ME, Densmore JJ, Pawluczkowycz AW, et al: Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177:7435-7443, 2006
45. Lundin J, Kimby E, Björkholm M, et al: A. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002